T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
Free full text in Europe PMC
Abstract
Background
In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are able to trigger a T helper 1 (Th1) anticancer immune response that contribute to treatment success. T helper 1 immune response is characterised by the expression of the transcription factor T-bet in CD4 T lymphocytes. We hypothesised that the presence of such T cells in the tumour immune infiltrates following neoadjuvant chemotherapy would predict patient survival.Methods
In a series of 102 consecutive HER2-overexpressing breast cancer patients treated by neoadjuvant chemotherapy incorporating antracyclines or taxane and trastuzumab, we studied by immunohistochemistry the peritumoral lymphoid infiltration by T-bet+ lymphocytes before and after chemotherapy in both treatment groups. Kaplan-Meier analysis and Cox modelling were used to assess relapse-free survival (RFS).Results
Fifty-eight patients have been treated with trastuzumab-taxane and 44 patients with anthracyclines-based neoadjuvant chemotherapy. The presence of T-bet+ lymphocytes in peritumoral lymphoid structures after chemotherapy was significantly more frequent in patients treated with trastuzumab-taxane (P=0.0008). After a median follow-up of 40 months, the presence of T-bet+ lymphocytes after neoadjuvant chemotherapy confers significantly better RFS (log-rank test P=0.011) only in patients treated with trastuzumab-taxane. In this population, multivariate Cox regression model showed that only the presence of T-bet+ lymphocytes in peritumoral lymphoid structures after neoadjuvant chemotherapy was independently associated with improved RFS (P=0.04).Conclusion
These findings indicate that the tumour infiltration by T-bet+ Th1 lymphocytes following neoadjuvant trastuzumab-taxane may represent a new independent prognostic factor of improved outcome in HER2-overexpressing breast carcinoma.Free full text
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
Background:
In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are able to trigger a T helper 1 (Th1) anticancer immune response that contribute to treatment success. T helper 1 immune response is characterised by the expression of the transcription factor T-bet in CD4 T lymphocytes. We hypothesised that the presence of such T cells in the tumour immune infiltrates following neoadjuvant chemotherapy would predict patient survival.
Methods:
In a series of 102 consecutive HER2-overexpressing breast cancer patients treated by neoadjuvant chemotherapy incorporating antracyclines or taxane and trastuzumab, we studied by immunohistochemistry the peritumoral lymphoid infiltration by T-bet+ lymphocytes before and after chemotherapy in both treatment groups. Kaplan–Meier analysis and Cox modelling were used to assess relapse-free survival (RFS).
Results:
Fifty-eight patients have been treated with trastuzumab–taxane and 44 patients with anthracyclines-based neoadjuvant chemotherapy. The presence of T-bet+ lymphocytes in peritumoral lymphoid structures after chemotherapy was significantly more frequent in patients treated with trastuzumab–taxane (P=0.0008). After a median follow-up of 40 months, the presence of T-bet+ lymphocytes after neoadjuvant chemotherapy confers significantly better RFS (log-rank test P=0.011) only in patients treated with trastuzumab–taxane. In this population, multivariate Cox regression model showed that only the presence of T-bet+ lymphocytes in peritumoral lymphoid structures after neoadjuvant chemotherapy was independently associated with improved RFS (P=0.04).
Conclusion:
These findings indicate that the tumour infiltration by T-bet+ Th1 lymphocytes following neoadjuvant trastuzumab–taxane may represent a new independent prognostic factor of improved outcome in HER2-overexpressing breast carcinoma.
Neoadjuvant chemotherapy has allowed oncologists to assess treatment response, and to tailor their treatments. Pathologic complete response (pCR) after neoadjuvant chemotherapy has been described as a strong indicator of chemosensitivity, justifying its use as a surrogate marker of survival (Kuerer et al, 1999). Although chemotherapy mainly acts directly by cytotoxic effect on tumour cells, recent works indicate that some chemotherapies also have the ability to harness the host's immune system to fight against its tumour (Zitvogel et al, 2008). For example, in HER2-overexpressing breast cancer, trastuzumab, an anti-HER2 monoclonal antibody, has drastically improved patient prognosis in adjuvant and neoadjuvant (Buzdar et al, 2005; Piccart-Gebhart et al, 2005; Romond et al, 2005; Untch et al, 2010) setting when combined with chemotherapy. Trastuzumab is often associated with taxanes in synergistic chemotherapy regimens. Trastuzumab kills cancer cells by blocking intracellular transduction signals, but also restrain their growth by activating the host's immune system through antibody-dependent cellular cytotoxicity (ADCC) (Arnould et al, 2006). This event leads to T helper 1 (Th1) activation of T cells, an adaptative immune response characterised by T cells production of interferon-γ (IFN-γ), and implicated in cancer growth control (Dhodapkar et al, 2002). Moreover, recent works indicated that taxanes could also exert immunostimulatory effects against breast cancer (Lee et al, 2000; Tsavaris et al, 2002; Carson et al, 2004), notably by inducing Th1 immune response. There is increasing evidence that the development of Th1 adaptive immunity is associated with improved outcome in various cancer types (Zhang et al, 2003; Galon et al, 2006; Roepman et al, 2009). T-bet (TBX21) is a Tbox transcription factor known to be crucial for the development of effector Th1 CD4 T cells (Mullen et al, 2001), and the most specific marker of this T-cell subset.
The current study was undertaken to analyse the prognostic role of Th1 polarised T cells expressing T-bet in intratumoral lymphoid structures, in patients undergoing neoadjuvant chemotherapy incorporating or not trastuzumab and taxane for HER2-overexpressing breast cancer. Interestingly, this study reveals that the presence of T-bet+ lymphocytes in intratumoral lymphoid structures after neoadjuvant chemotherapy is significantly more frequent after trastuzumab–taxane-based chemotherapy, and could be a new prognostic biomarker of improved survival in this group of patients.
Patients
We retrospectively studied cancer-tissue specimens from 660 patients who underwent neoadjuvant chemotherapy for non-metastatic breast cancer at the Georges François Leclerc Cancer Center, Dijon, and Sainte Marie Private Hospital, Chalon sur Saone, France, from January 1981 to November 2008. In all these patients, HER2 status was determined using the Herceptest scoring method, considering only three-grade score as determining HER2-positive tumours. For patients with two-grade score, a chromogenic in situ hybridisation was performed to determine HER2 overexpression. According to this test, we only recruited in this study the 102 consecutive HER2-overexpressing breast cancers in which we have paraffin-embedded initial tumour biopsies and surgical specimens for immunohistochemical study. The study was approved by the ethical local committee, and patients gave written informed consent for the use of samples from their tumours for future investigations at the time of the diagnosis. Histoprognostic grade was defined according to the modified Bloom and Richardson method by Elston and Ellis. The steroid hormone receptors statuses were determined using immunochemistry. Chemotherapy treatment consisted of an anthracycline-based regimen from 1981 to 2000: FEC 100 (epirubicin 100mg
m–2, cyclophosphamide 500
mg
m–2, and 5-fluorouracil 500
mg
m–2) or FAC (adriamycine 50
mg
m–2, cyclophosphamide 500
mg
m–2, and 5-fluorouracil 500
mg
m–2). From 2001 to 2007, the regimen consisted in trastuzumab (2
mg
kg–1 per week) associated with chemotherapy by docetaxel 100
mg
m–2 or by docetaxel 75
mg
m–2 + carboplatin AUC 6. After six cycles of chemotherapy, breast surgery (conservative whenever possible) and axillary lymph node dissection were mandatory 3–5 weeks after the last cycle. Adjuvant radiotherapy was administrated in all patients and postsurgical hormonal therapy was administrated in patients with hormone receptor-positive tumours. Histological response was determined on surgical specimens: breast tissue without residual malignant epithelial invasive tumour, and associated with no microscopic evidence of tumour cell in axillary specimens, was considered as pCR.
Immunohistochemical labelling
Immunohistochemistry used monoclonal antibodies against the T-bet (TBX21) transcription factor (Santa Cruz, Heidelberg, Germany, clone 4B10). Antigen retrieval was carried out by heating slides for 15min at 95°C in 1
mmol
l–1 EDTA. Labelling was detected using the Dako Envision system (Dako, Trappes, France). The stained arrays were counterstained with haematoxylin and mounted in Aquamount (Dako). Positive and negative staining controls were carried out with paraffin tonsil sections using T-bet monoclonal antibody and an isotype-matched negative control antibody.
Presence of T-bet+ lymphocytes
The presence or absence of T-bet+ lymphocytic infiltration was evaluated by two independent physicians (FG and SL) in the lymphoid peritumoral areas of the entire tissue section. All samples were previously anonymised and blinded to the clinicopathologic data. For each tissue section, the presence or absence of T-bet+ cells were established after the analysis of 20 high power fields (20 × ). T-bet induction was defined by the absence of T-bet+ T cells on the initial tumour specimen, associated with apparition of T-bet+ lymphocytes in intratumoral lymphoid structures on surgical specimen after completion of chemotherapy in the same patient. The results of the analyses conducted by each independent pathologist were subsequently compared (κ score was 0.96). Discrepancies between the two observers were reviewed jointly to reach a consensus. As a number of tumour without T-bet+ cells could be found, we dichotomise patient between the presence and absence of T-bet+ cells. When T-bet+ cells were found present in the tumour, we always observed these cells in tertiary lymphoid organs closed to tumour bed. These cells could be enumerated and represent around 3–15 cells per lymphoid structure.
Statistical analyses
Qualitative variables were described as frequencies and percentages. The association of variables was evaluated with the χ2 test. The Wilcoxon test was used to compare non-continuous variables in paired samples as appropriate. Relapse-free survival (RFS) was calculated from the date of diagnosis until the date of relapse (local or metastatic). Alive or dead patients without relapse were censored at the last follow-up. Follow-up was calculated using reverse Kaplan–Meier method. Relapse-free survival probabilities were estimated using Kaplan–Meier method and were compared by the log-rank test. The hazards ratios (HRs) with 95% confidence interval (CI) were calculated using univariate Cox proportional hazards regression modelling. All variables with a univariate Cox P-value 0.20 were eligible for multivariate analyses. Correlations between co-variables were first tested for eligible variables. To prevent collinearity, when two variables were significantly correlated, one variable was retained according to its clinical relevance or to the value of the likelihood ratio. Finally, multivariate Cox proportional hazards regression modelling was applied to assess independent prognosis effect for RFS. All reported P-values are two sided. The statistical significance level was set at P<0.05. Analyses were performed using STATA (version 11.0, Stata Corp, College Station, TX, USA).
Patient characteristics
In total, 102 patients with a confirmed HER2-overexpressing breast cancer were included in this analysis. Patient and tumour characteristics are reported in Table 1. Half of all patients presented with stage T3 or T4 tumour and 72% had clinically detectable axillary lymph node involvement at diagnosis. Half the patients presented with high tumour grade (SBR III) and/or negative oestrogen receptor. Neoadjuvant chemotherapy was given every 3 weeks for a total of six cycles, and consisted of an anthracycline-based regimen in 44 cases, and trastuzumab–taxane-based regimen in 58 cases. Classic histological analysis of surgical specimens revealed a pCR in 32 cases (31%). Median follow-up period was 40 months (range 7–144). Kaplan–Meier curves of pCR vs no-pCR groups for both cohorts were presented in Supplementary Figure 1.
Table 1
|
Patients treated with anthracyclines (n=44)
|
Patients treated with taxane–trastuzumab (n=58)
| ||||
|---|---|---|---|---|---|
| N | % | N | % | P | |
| Age (years) | |||||
| 24 | 54 | 32 | 55 | ||
| 20 | 46 | 26 | 45 | 0.89 | |
| Tumour initial stage | |||||
| 18 | 41 | 36 | 62 | ||
| 26 | 59 | 22 | 38 | 0.06 | |
| Axillary nodal status | |||||
| 38 | 86 | 35 | 60 | ||
| 6 | 14 | 23 | 40 | 0.01 | |
| Tumour grade | |||||
| 18 | 41 | 37 | 64 | ||
| 26 | 59 | 21 | 36 | 0.04 | |
| Oestrogen receptor | |||||
| 17 | 39 | 33 | 57 | ||
| 27 | 61 | 25 | 43 | 0.10 | |
| Pathological complete response | |||||
| 8 | 18 | 24 | 41 | ||
| 36 | 82 | 34 | 59 | 0.02 | |
| T-bet+ infiltrates before CT | |||||
| 9 | 21 | 13 | 22 | ||
| 35 | 79 | 45 | 78 | 0.99 | |
| T-bet+ infiltrates after CT | |||||
| 7 | 16 | 29 | 50 | ||
| 37 | 84 | 29 | 50 | 0.0008 | |
| T-bet+ induction | |||||
| 6 | 14 | 22 | 38 | ||
| 38 | 86 | 36 | 62 | 0.01 | |
| Relapse | |||||
| 26 | 59 | 14 | 24 | ||
| 18 | 41 | 44 | 76 | 0.0007 | |
| Death | |||||
| 23 | 52 | 2 | 4 | ||
| 21 | 48 | 56 | 96 | <0.0001 | |
Abbreviation: CT=chemotherapy.
Comparisons between the two groups of treatment reveal that patients treated after 2001 with trastuzumab–taxane-based neoadjuvant chemotherapy had significantly less high-grade tumours and axillary lymph node involvement. Pathologic complete response was more frequently achieved in trastuzumab–taxane group (41% vs 18% P=0.02) (Table 1).
The presence of T-bet+ lymphocytes were analysed in the whole tumour and in the peritumoral areas. T-bet + cells were only located in peritumoral lymphoid structures (Figure 1). Before chemotherapy, T-bet+ cells were rare and the percentage of positive tumour did not differ between the two treatment groups (P=0.99). After chemotherapy, our analysis revealed an absence of T-bet+ cells in 66 tumours, the presence of 3–5 T-bet+ cells in 25 tumours and presence of more than five T-bet+ cells in 11 tumours. Importantly, we did not observe any correlation between residual tumour size and level of T-bet infiltration (low vs high infiltration). We have, therefore, decided to use only a dichotomic classification (absence vs presence of T-bet+ cells). Interestingly, after neoadjuvant chemotherapy, 50% of patients treated with trastuzumab–taxane had T-bet+ cells infiltration in peritumoral lymphoid structures, vs only 16% of patients treated with antracyclines (P=0.0008). T-bet induction was significantly more frequent in patients treated with trastuzumab and taxane (P=0.01) (Table 1).
(A) Haematoxylin–eosin–safran labelling of an HER2-overexpressing breast cancer. White arrows indicate tumour islets and the black arrow the paratumoral lymphoid structure (Magnification × 10). Immunohistochemical T-bet staining of paraffin-embedded breast cancer overexpressing HER2. (B) Representative tumour with lymphoid structure devoid of T-bet+ lymphocyte infiltration. (C) Representative tumour with lymphoid structure with T-bet+ lymphocyte infiltration. White arrows show tumour islets (magnification × 10). A detail of lymphoid infiltrate is shown on × 40 magnification.
Association of outcomes with immunological findings
In patients treated with anthracyclines, univariate Cox proportional analysis indicated that neither the presence of T-bet+ cells before, nor after neoadjuvant chemotherapy, nor T-bet+ cell induction were associated with an increased risk of relapse (RFS). By contrast, in patients treated with trastuzumab–taxane, the presence of T-bet+ cells in peritumoral lymphoid structures after chemotherapy (P=0.02; HR: 5.6; 95% CI: 1.25–25) and T-bet+ cells induction (P=0.04; HR: 6.7; 95% CI: 1.08–38) were associated with a better RFS (Table 2). The presence of T-bet+ cells after neoadjuvant chemotherapy confers significantly better RFS (log-rank test P=0.011) only in patients treated with trastuzumab and taxane (Figure 2A and B). We did not observe any significant correlation between T-bet induction and pCR thus indicating that T-bet induction is a prognostic factor independent of the pathological response. In this population, multivariate Cox regression model showed that only the presence of T-bet+ cells in peritumoral lymphoid structures after neoadjuvant chemotherapy was independently associated with improved RFS (P=0.04; HR: 4.76; 95% CI: 1.07–20) (Table 3). Inclusion of pCR in the multivariate model did not change the capacity of T-bet expression to predict RFS. Correlation between T-bet presence after chemotherapy and classical clinical prognostic factors demonstrates that no classical prognostic factors are linked to T-bet expression after chemotherapy (Table 4).
Presence of T-bet+ T cells in peritumoral lymphoid structure predicts better RFS in patients treated with neoadjuvant taxanes–trastuzumab-based neoadjuvant chemotherapy. Kaplan–Meier curves for RFS stratified according to the presence or absence of T-bet+ T cells after neoadjuvant chemotherapy in (A) patients treated with anthracyclines, (B) patients treated with taxanes–trastuzumab. P-values were calculated using the log-rank test.
Table 2
|
Anthracyclines (n=44)
|
Taxane–trastuzumab (n=58)
| |||||
|---|---|---|---|---|---|---|
| Univariate HR | 95% CI | P | Univariate HR | 95% CI | P | |
| Age (years) | ||||||
| 1 | 1 | |||||
| 0.61 | 0.28–1.31 | 0.20 | 2.9 | 0.82–10.8 | 0.09 | |
| Tumour initial stage | ||||||
| 1 | 1 | |||||
| 1.10 | 0.51–2.41 | 0.79 | 1.91 | 0.64–5.7 | 0.24 | |
| Axillary nodal status | ||||||
| 1 | 1 | |||||
| 1.32 | 0.40–4.40 | 0.64 | 1.62 | 0.50–5.25 | 0.42 | |
| Tumour grade | ||||||
| 1 | 1 | |||||
| 0.67 | 0.31–1.45 | 0.30 | 1.49 | 0.50–4.40 | 0.47 | |
| Oestrogen receptor | ||||||
| 1 | 1 | |||||
| 1.19 | 0.55–2.60 | 0.65 | 2.8 | 0.92–8.3 | 0.07 | |
| Pathological complete response | ||||||
| 1 | 1 | |||||
| 2.32 | 0.69–7.60 | 0.17 | 2 | 0.62–6.30 | 0.25 | |
| T-bet+ infiltrates before CT | ||||||
| 1 | 1 | |||||
| 2.6 | 0.80–9.1 | 0.11 | 1.51 | 0.34–6.7 | 0.58 | |
| T-bet+ infiltrates after CT | ||||||
| 1 | 1 | |||||
| 0.74 | 0.28–1.96 | 0.55 | 5.6 | 1.25–25 | 0.02 | |
| T-bet+ induction | ||||||
| 1 | 1 | |||||
| 0.55 | 0.20–1.49 | 0.24 | 6.7 | 1.08–38 | 0.04 | |
Abbreviations: CI=confidence interval; CT=chemotherapy; HR=hazard ratio.
Table 3
| Multivariate HR | 95% CI | P | |
|---|---|---|---|
| Age (years) | |||
| 1 | |||
| 1.75 | 0.37–8.22 | 0.47 | |
| Oestrogen receptor | |||
| 1 | |||
| 1.88 | 0.51–7.14 | 0.34 | |
| T-bet+ infiltrates after CT | |||
| 1 | |||
| 4.76 | 1.07–20 | 0.04 | |
Abbreviations: CI=confidence interval; CT=chemotherapy; HR=hazard ratio.
Table 4
|
Presence of T-bet+ cells
|
Absence of T-bet+ cells
| ||||
|---|---|---|---|---|---|
| N | % | N | % | P | |
| Age (years) | |||||
| 14 | 49 | 18 | 62 | ||
| 15 | 51 | 11 | 38 | 0.43 | |
| Tumour initial stage | |||||
| 21 | 72 | 15 | 51 | ||
| 8 | 28 | 14 | 49 | 0.17 | |
| Axillary nodal status | |||||
| 18 | 62 | 17 | 58 | ||
| 11 | 38 | 12 | 42 | 0.99 | |
| Tumour grade | |||||
| 19 | 65 | 18 | 62 | ||
| 10 | 35 | 11 | 38 | 0.99 | |
| Oestrogen receptor | |||||
| 18 | 62 | 15 | 51 | ||
| 11 | 38 | 14 | 49 | 0.59 | |
| Pathological complete response | |||||
| 15 | 51 | 9 | 31 | ||
| 14 | 49 | 20 | 69 | 0.18 | |
Abbreviation: CT=chemotherapy.
This study highlights the importance of host's immune response in the prognosis of breast cancer, and the interaction between chemotherapy regimen and the immune system in this setting. In our series, neoadjuvant chemotherapy incorporating taxanes and trastuzumab seems to influence the apparition of a Th1 immune response in the intratumoral lymphoid structures in contrast to anthracyclines. Moreover, the presence of these T-bet+ lymphocytes after neoadjuvant trastuzumab–taxane chemotherapy is associated with better RFS in this population.
In recent years, convincing data supporting the prognostic role of immune response against cancer was emerging (Zitvogel et al, 2006). In cancer setting, host protection is largely afforded via the generation of Th1 response, in which the transcription factor T-bet is playing a key role (Mullen et al, 2001). In patients with colorectal carcinoma, the presence of mRNA encoding molecules expressed by Th1 cells, such as T-bet, correlates with reduced metastatic invasion and increased survival (Galon et al, 2006). However, the prognostic role of T-bet+ lymphocytes in breast cancer has not been yet investigated.
Trastuzumab plus docetaxel is an approved anticancer regimen that is used worldwide for the treatment of HER2-overexpressing breast cancer notably in neoadjuvant setting (Coudert et al, 2007). Trastuzumab contains an IgG1 Fc structure. When the Fcγ receptor on immune effector cells detects the Fc portion of the antibody bound to target cells, immune effector cells are recruited to attack the target cells (Lazar et al, 2006). In vitro, this process is termed as ADCC. Laboratory studies have shown that HER2-overexpressing breast cancer cell lines are susceptible to ADCC in the presence of trastuzumab (Carson et al, 2001; Parihar et al, 2002; Gennari et al, 2004), and in vivo activity of trastuzumab has been correlated with significantly increased number of peritumoral lymphocytes and monocytes and in vitro ADCC (Gennari et al, 2004; Arnould et al, 2006). Additional studies have indicated that NK cells are keys for trastuzumab-mediated ADCC (Cooley et al, 1999; Clynes et al, 2000; Mimura et al, 2005). Nonetheless, activated NK cells, by their secretion of INF-γ could activate macrophages, which in turn produce interleukin-12 (IL-12), which is playing a key role in Th1 polarisation (Manetti et al, 1993). Thus, induction of T-bet, the pathognomic marker of Th1 polarisation could be a surrogate marker of the immunological effects of trastuzumab, but also of taxanes. Indeed, recent works indicated that taxanes could exert immunostimulatory effects against breast cancer. Thus, paclitaxel is able to stimulate the secretion by macrophages of proinflammatory and Th1 cytokines such as IL-1β or IL-12 (Mullins et al, 1998; Chan and Yang, 2000). Preclinical studies have shown that breast cancer bearing mice responding to docetaxel chemotherapy harboured strong tumoral infiltration with T lymphocytes and NK cells (Mason et al, 2001), and these observations have been also reported in breast cancer patients (Tong et al, 2000; Demaria et al, 2001). In 227 breast cancer patients, Carson et al (2004) demonstrated that T-cell activation was significantly higher in patients receiving taxanes compared with non-containing taxanes regimens. In patients with metastatic breast cancer, Tsavaris et al (2002) found that patients responding to paclitaxel or docetaxel-based chemotherapy harboured a significant increase in Th1 cytokine serum levels (IL-2 and INF-γ). All these immunological findings may partially explain the synergistic activity of trastuzumab and docetaxel in the treatment of HER2-overexpressing breast cancer and the excellent clinical outcome afforded by this combination in neoadjuvant setting (Guiu et al, 2011). Thus, efforts addressing the mechanisms mediating trastuzumab and taxanes immunological activity, and biomarkers of this activity would allow for optimal use of this treatment for patients with HER2-overexpressing breast cancer.
In order to prove that T-bet induction was none specific than trastuzumab regimen, we used a control group of patients treated with anthracyclines-based chemotherapy. Preclinical data obtained in mouse have suggested the involvement of immune system in the antitumour response mediated by anthracyclines (Apetoh et al, 2007). However, in the present study, we did not observe a significant T-bet induction in intratumoral lymphoid structures after chemotherapy in patients treated with an anthracycline-based regimen. The explanation for this discrepancy might lie in the fact that anthracylines primarily activate CD8 (and not CD4) T cells to produce IFN-γ in mouse models and the transcription factor T-bet drives IFN-γ secretion in CD4 T cells but not in CD8 T cells. These results thus suggest that the use of T-bet expression as a biomarker of the potential immunologic effects of anthracyclines might not be appropriate. In addition, since taxanes are always associated with trastuzumab, we could not determine if the immune response induced by taxanes plus trastuzumab is due to taxanes, trastuzumab, or their combination. However, the previous results obtained by Zitvogel et al, suggesting the inability of docetaxel to induce an immunogenic cell death, would support the hypothesis that the combination of taxanes plus trastuzumab is required to elicit an immune response against cancer.
One possible bias of our study is the selection of the control group. Because of the retrospective design of the study, the control group might have some differences in prognostic variables compared with the taxanes plus trastuzumab group. These differences might have affected our observed results.
In conclusion, this study highlights another possible proof-of-principle of immune modulation by the trastuzumab–taxane combination in HER2-overexpressing breast carcinoma, and suggests that T-bet induction or the presence of T-bet+ lymphocytes in intratumoral lymphoid structures after neoadjuvant chemotherapy could be a new biomarker of the long-term efficacy of this regimen, which could help to select high-risk patients for additional therapies after neoadjuvant chemotherapy. In a previous work, we have demonstrated that the CD8/Foxp3 ratio in tumour bed after chemotherapy is associated with a favourable outcome. This ratio is applicable to both patients treated with anthracycline and patients treated with trastuzumab plus taxanes. T-bet expression is a predictor of outcome only in patients treated with trastuzumab plus taxanes. Further studies are warranted to test if the association of CD8, Foxp3 and T-bet labelling will further optimise the prognostic prediction in patients treated with trastuzumab plus taxanes. The issue of whether T-bet might become a clinically usable prognostic marker in breast carcinoma will need to be evaluated in other larger series of patients, and analysis will have to be stratified on breast molecular subtype, and on chemotherapy regimen.
Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
Supplementary Figure 1
Supplementary Figure legend
- Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050–1059 [Abstract] [Google Scholar]
- Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–267 [Europe PMC free article] [Abstract] [Google Scholar]
- Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685 [Abstract] [Google Scholar]
- Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31: 3016–3025 [Abstract] [Google Scholar]
- Carson III WE, Shapiro CL, Crespin TR, Thornton LM, Andersen BL (2004) Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 10: 3401–3409 [Abstract] [Google Scholar]
- Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49: 181–185 [Abstract] [Google Scholar]
- Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446 [Abstract] [Google Scholar]
- Cooley S, Burns LJ, Repka T, Miller JS (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27: 1533–1541 [Abstract] [Google Scholar]
- Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 25: 2678–2684 [Abstract] [Google Scholar]
- Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF (2001) Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7: 3025–3030 [Abstract] [Google Scholar]
- Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation of cCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195: 125–133 [Europe PMC free article] [Abstract] [Google Scholar]
- Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960–1964 [Abstract] [Google Scholar]
- Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650–5655 [Abstract] [Google Scholar]
- Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert B (2011) Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Ann Oncol 22: 321–328 [Abstract] [Google Scholar]
- Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460–469 [Abstract] [Google Scholar]
- Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 4005–4010 [Europe PMC free article] [Abstract] [Google Scholar]
- Lee M, Yea SS, Jeon YJ (2000) Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol 22: 615–621 [Abstract] [Google Scholar]
- Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199–1204 [Europe PMC free article] [Abstract] [Google Scholar]
- Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18: 599–606 [Abstract] [Google Scholar]
- Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898–4904 [Abstract] [Google Scholar]
- Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, Reiner SL (2001) Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292: 1907–1910 [Abstract] [Google Scholar]
- Mullins DW, Koci MD, Burger CJ, Elgert KD (1998) Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol Immunotoxicol 20: 473–492 [Abstract] [Google Scholar]
- Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110: 983–992 [Europe PMC free article] [Abstract] [Google Scholar]
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672 [Abstract] [Google Scholar]
- Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N (2009) An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 15: 284–290 [Abstract] [Google Scholar]
- Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684 [Abstract] [Google Scholar]
- Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J (2000) Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 23: 463–472 [Abstract] [Google Scholar]
- Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21–27 [Europe PMC free article] [Abstract] [Google Scholar]
- Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28: 2024–2031 [Abstract] [Google Scholar]
- Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203–213 [Abstract] [Google Scholar]
- Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59–73 [Abstract] [Google Scholar]
- Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715–727 [Abstract] [Google Scholar]
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK
Full text links
Read article at publisher's site: https://doi.org/10.1038/bjc.2011.261
Read article for free, from open access legal sources, via Unpaywall:
https://www.nature.com/articles/bjc2011261.pdf
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Context-dependent T-BOX transcription factor family: from biology to targeted therapy.
Cell Commun Signal, 22(1):350, 04 Jul 2024
Cited by: 1 article | PMID: 38965548 | PMCID: PMC11225425
Review
Free full text in Europe PMC
Towards targeting the breast cancer immune microenvironment.
Nat Rev Cancer, 24(8):554-577, 05 Jul 2024
Cited by: 3 articles | PMID: 38969810
Review
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Breast, 73:103668, 25 Dec 2023
Cited by: 0 articles | PMID: 38176305 | PMCID: PMC10791571
Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer.
Oncoimmunology, 13(1):2296713, 22 Dec 2023
Cited by: 1 article | PMID: 38170155 | PMCID: PMC10761100
Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade.
Front Immunol, 14:1267621, 31 Oct 2023
Cited by: 4 articles | PMID: 38022643 | PMCID: PMC10643871
Go to all (38) article citations
Data
Data behind the article
This data has been text mined from the article, or deposited into data resources.
BioStudies: supplemental material and supporting data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol, 19(1):115-126, 23 Nov 2017
Cited by: 229 articles | PMID: 29175149
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Ann Oncol, 24(8):1999-2004, 05 Apr 2013
Cited by: 44 articles | PMID: 23562929 | PMCID: PMC3718505
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Ann Oncol, 25(1):81-89, 21 Nov 2013
Cited by: 40 articles | PMID: 24273046
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Semin Oncol, 28(1 suppl 3):13-19, 01 Feb 2001
Cited by: 124 articles | PMID: 11301370
Review